Robbins Farley’s CRISPR Therapeutics CRSP Stock Holding History

Robbins Farley’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$164	Hold	3	–	–	﹤0.01%	151
2026 Q1	$143	Hold	3	–	–	﹤0.01%	136
2025 Q4	$158	Sell	3 -10	-77%	-$599	﹤0.01%	139
2025 Q3	$843	Buy	13 +10	+333%	+$574	﹤0.01%	148
2025 Q2	$146	Hold	3	–	–	﹤0.01%	165
2025 Q1	$103	Hold	3	–	–	﹤0.01%	148
2024 Q4	$119	Hold	3	–	–	﹤0.01%	147
2024 Q3	$141	Hold	3	–	–	﹤0.01%	146
2024 Q2	$163	Hold	3	–	–	﹤0.01%	158
2024 Q1	$205	Hold	3	–	–	﹤0.01%	158
2023 Q4	$188	Hold	3	–	–	﹤0.01%	163
2023 Q3	$137	Buy	+3	New	+$155	﹤0.01%	172
2023 Q2	–	Sell	-3	Closed	-$136	–	168
2023 Q1	$136	Hold	3	–	–	﹤0.01%	183
2022 Q4	$122	Hold	3	–	–	﹤0.01%	176
2022 Q3	$0	Buy	+3	New	+$217	﹤0.01%	138
2022 Q2	–	Sell	-3	Closed	–	–	129
2022 Q1	$0	Buy	+3	New	+$188	﹤0.01%	140

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Robbins Farley's CRSP Position: Q2 2026 in Review

Robbins Farley held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 3 shares worth $164. The position accounts for ﹤0.01% of the portfolio, ranked #151.

Robbins Farley first reported a position in CRSP in Q1 2022 and has held it in 16 quarters since. The position peaked at $843 in Q3 2025. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Robbins Farley held 3 shares of CRISPR Therapeutics worth $164 as of Q2 2026.
Robbins Farley left its CRISPR Therapeutics share count unchanged in Q2 2026.
CRISPR Therapeutics made up ﹤0.01% of Robbins Farley's portfolio in Q2 2026, its #151 holding.
Robbins Farley first reported a position in CRISPR Therapeutics in Q1 2022 and has held it in 16 quarters since.
Robbins Farley's CRISPR Therapeutics position peaked at $843 in Q3 2025.
521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Robbins Farley's 13F filing for Q2 2026, filed 23 Jul 2026.